Screener
Ligand Pharmaceuticals LGND Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Long-term contingent liabilities | 2,382 | 2,934 |
| Long-term operating lease liabilities | 3,777 | 4,204 |
| Convertible senior notes, net | 1,126,594 | 446,192 |
| Deferred income taxes, net | 21,654 | 36,019 |
| Other long-term liabilities | 17,216 | 16,629 |
| Total liabilities | 1,218,359 | 543,425 |
| Commitments and contingencies | ||
| Stockholders’ equity: |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's deferred tax assets?
- Ligand Pharmaceuticals (LGND) reported deferred tax assets of $21.65M in Q2 2026.
- How has Ligand Pharmaceuticals's deferred tax assets changed year-over-year?
- Ligand Pharmaceuticals's deferred tax assets decreased by 32.8% year-over-year, from $32.25M to $21.65M.
- What is the long-term trend for Ligand Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's deferred tax assets has grown at a -11.0% compound annual growth rate (CAGR), from $64.6M to $36.02M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.
Ask your AI about Ligand Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude